In this webinar, Dr. Kevin Wang will discuss a precision medicine approach for treating traumatic brain injury which uses phenotype biomarkers to monitor disease course and develop novel therapies.
The Biogen-developed treatment, called lecanemab, appears to have a more clear-cut effect on slowing the disease than the company’s previous Alzheimer’s drug, Aduhelm.
An interesting but preliminary biomarker study’s reception illustrates the challenges of conducting and communicating nuanced research in the era of social media.
Mariella Bodemeier Loayza Careaga, PhD | Dec 4, 2023 | 6 min read
Haydeh Payami helped uncover the genetic basis of Parkinson’s disease. Now, she hopes to find new ways to treat the disease by studying the gut microbiome.
The University of Toronto and University of Vienna pharmacologist developed L-dopa, a precursor to dopamine that remains the most widely used therapy for Parkinson’s disease.